<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485600</url>
  </required_header>
  <id_info>
    <org_study_id>P14-506</org_study_id>
    <nct_id>NCT02485600</nct_id>
  </id_info>
  <brief_title>Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients</brief_title>
  <official_title>Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, postmarketing, observational study to document health outcomes, in
      Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa
      (levodopa/carbidopa intestinal gel).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2015</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in participant's motor symptoms</measure>
    <time_frame>Baseline, Day 1, Month 3, Month 6, and every 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Unified Parkinson's Disease Rating Scale (UPDRS) Part II, III, V and Part IV items 33-35; items 32 &amp; 39 modified as per MDS-UPDRS, and the Freezing of Gait Questionnaire (FOGQ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the cognitive functions.</measure>
    <time_frame>Baseline, Day 1, and every 12 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Montreal Cognitive Assessment (MoCa).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Parkinson's Disease Questionnaire (PDQ-39)</measure>
    <time_frame>Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Parkinson's Disease Questionnaire (PDQ-39)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in caregiver burden</measure>
    <time_frame>Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Zarit Care Giver Burden Questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the non-motor symptoms.</measure>
    <time_frame>Baseline, Day 1, Month 3, and very 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Non-Motor symptoms Scale (NMS) and the Parkinson's Disease Sleep Scale (PDSS-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in caregiver work productivity</measure>
    <time_frame>Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated by the Work Productivity and Activity Information Questionnaire (WPAI - care giver)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the participant's Healthcare Resource Utilization</measure>
    <time_frame>Baseline, Month 3, and every 6 months thereafter up to 48 months</time_frame>
    <description>Evaluated via the Health Care Resources Utilization Questionnaire (HCRU).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">88</enrollment>
  <condition>Parkinson Disease (PD)</condition>
  <arm_group>
    <arm_group_label>DUODOPA patients.</arm_group_label>
    <description>Patients starting DUODOPA treatment at time of enrollment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will consist of patients eligible for DUODOPA treatment according to
        the DUODOPA Product Monograph (DPM) approved by Health Canada and according to the
        reimbursement criteria accepted by the Canadian Provincial Health Authorities or private
        insurance companies.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with advanced Parkinson's Disease

          -  Prescribed Duodopa by his/her treating physician.

        Exclusion Criteria:

          -  Patients who were previously treated with Duodopa.

          -  Presence of other condition that, in the opinion of the treating physician, prohibits
             the patient from participating in the study or obscures the assessment of the
             treatment of advanced PD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary /ID# 151948</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre /ID# 135979</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface Clinic, CA /ID# 162092</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences /ID# 148808</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital /ID# 144942</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre /ID# 138434</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital /ID# 135981</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital /ID# 135980</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC /ID# 138334</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Notre-Dame Hospital /ID# 135977</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr Hosp Enfant Jesus /ID# 138435</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS Alphonse-Desjardins, CHAU de Levis /ID# 144941</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS - Hopital Fleurimont /ID# 148811</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cadence</keyword>
  <keyword>Duodopa</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>LCIG</keyword>
  <keyword>Levodopa-carbidopa intestinal gel</keyword>
  <keyword>Observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

